MAM
VNDA icon

Martingale Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Martingale Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$320K Buy
52,343
+19,229
+58% +$126K 0.01% 745
2026
Q1 		$229K Hold
33,114
– – 0.01% 763
2025
Q4 		$292K Buy
33,114
+15,431
+87% +$84.9K 0.01% 701
2025
Q3 		$88.2K Sell
17,683
-2,400
-12% -$11.1K ﹤0.01% 755
2025
Q2 		$94.8K Sell
20,083
-2,826
-12% -$12.4K ﹤0.01% 776
2025
Q1 		$105K Sell
22,909
-41,900
-65% -$195K ﹤0.01% 758
2024
Q4 		$310K Sell
64,809
-5,200
-7% -$25K 0.01% 685
2024
Q3 		$328K Sell
70,009
-5,506
-7% -$29.5K 0.01% 701
2024
Q2 		$427K Hold
75,515
– – 0.01% 632
2024
Q1 		$310K Buy
75,515
+3,011
+4% +$12.1K 0.01% 706
2023
Q4 		$306K Sell
72,504
-7,718
-10% -$31.1K 0.01% 696
2023
Q3 		$347K Buy
80,222
+13,250
+20% +$73.6K 0.01% 663
2023
Q2 		$441K Buy
66,972
+18,303
+38% +$117K 0.01% 636
2023
Q1 		$330K Sell
48,669
-30,496
-39% -$214K 0.01% 695
2022
Q4 		$585K Buy
79,165
+2,520
+3% +$24.5K 0.01% 591
2022
Q3 		$758K Buy
76,645
+52,127
+213% +$550K 0.02% 517
2022
Q2 		$268K Sell
24,518
-5,400
-18% -$56K ﹤0.01% 759
2022
Q1 		$339K Sell
29,918
-46,518
-61% -$611K 0.01% 708
2021
Q4 		$1.2M Sell
76,436
-3,500
-4% -$61K 0.02% 446
2021
Q3 		$1.37M Buy
79,936
+13,700
+21% +$240K 0.02% 427
2021
Q2 		$1.43M Sell
66,236
-1,900
-3% -$34K 0.02% 316
2021
Q1 		$1.02M Buy
68,136
+5,909
+9% +$95.7K 0.01% 414
2020
Q4 		$818K Buy
62,227
+7,203
+13% +$86.7K 0.01% 492
2020
Q3 		$532K Sell
55,024
-44,500
-45% -$476K 0.01% 798
2020
Q2 		$1.14M Buy
+99,524
New +$1.13M 0.01% 699

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Martingale Asset Management's VNDA Position: Q2 2026 in Review

Martingale Asset Management increased its Vanda Pharmaceuticals (VNDA) stake by 58% in Q2 2026, buying an estimated $126K and bringing the position to 52,343 shares worth $320K. The position accounts for 0.01% of the portfolio, ranked #745.

Martingale Asset Management first reported a position in VNDA in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.43M in Q2 2021. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Martingale Asset Management held 52,343 shares of Vanda Pharmaceuticals worth $320K as of Q2 2026.
  • Martingale Asset Management bought 19,229 Vanda Pharmaceuticals shares in Q2 2026, an estimated $126K.
  • Vanda Pharmaceuticals made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #745 holding.
  • Martingale Asset Management first reported a position in Vanda Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Martingale Asset Management's Vanda Pharmaceuticals position peaked at $1.43M in Q2 2021.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.